Disclosed are a self-assembled catalase nanoparticle and a preparation method therefor and the use thereof. The self-assembled catalase nanoparticle of the present invention is obtained by dissolving catalase freeze-dried powder to obtain a catalase solution, adjusting the pH value of the catalase solution, and then centrifugating or filtering same to obtain a supernatant or a filtrate, and further thermally incubating the supernatant or filtrate. The self-assembling catalase nanoparticle of the present invention can be used in medicines or food products that promote immune cell growth and regulate organic immunity.

The present disclosure relates to microneedle devices and methods for treating a disease (for example, diabetes) using a degradable cross-linked gel for self-regulated delivery of a therapeutic agent (for example, insulin).

The present disclosure provides methods, compositions, and kits for in vitro cultivation of catalase-negative bacteria. The present disclosure further provides catalase-negative bacteria cultivated according to the methods described herein and bacterial stocks thereof.

Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.

The present disclosure provides compositions, methods, and kits that enable the in situ growth of polymers on or within a subject. In some aspects, the tissue-active monomers, including monomers comprising macromolecules, provide abroad set of material choices for synthetic tissue barriers. In additional aspects, the compositions, methods, and kits are useful for treating or preventing a disease or disorder.

A chemoenzymatic process for the preparation of 2,5-furan dicarboxylic acid includes contacting D-glucose with (i) at least two enzymes selected from the group consisting essentially of galactose oxidase, pyranose 2-oxidase, glucarate dehydratase, catalase and a combination thereof to produce an intermediate; and (ii) a heterogeneous metal catalyst to form 2,5-furan dicarboxylic acid.

An aqueous composition having increased protein stability is obtained by: a. determining a pH at which the protein has stability at the desired temperature; b. adding to the composition at least one displacement buffer wherein the displacement buffer has a pK.sub.a that is at least 1 unit greater or less than the pH of step (a); and c. adjusting the pH of the composition to the pH of step (a); wherein the aqueous composition does not comprise a conventional buffer at a concentration greater than about 2 mM and wherein the conventional buffer has a pK.sub.a that is within 1 unit of the pH of step (a).

Compositions comprising (i) lactate oxidase (LOX) and Catalase (CAT), preferably in a 1:1 molar ratio; or (ii) a fusion polypeptide comprising both LOX and CAT, e.g., LOXCAT, and methods of use thereof for reducing blood lactate levels, increasing blood pyruvate levels, and/or decreasing blood lactate/pyruvate ratio in a subject.

The present invention discloses a method for preparing L-glufosinate ammonium by biological enzymatic de-racemization, a glufosinate ammonium dehydrogenase mutant and a use thereof. The method for preparing L-glufosinate ammonium by biological enzymatic de-racemization includes catalyzing D,L-glufosinate ammonium as a raw material by a multi-enzyme catalysis system to obtain L-glufosinate ammonium. The enzyme catalysis system includes D-amino acid oxidase for catalyzing D-glufosinate ammonium in the D,L-glufosinate ammonium to 2-carbonyl-4-[hydroxy(methyl)phosphonyl]butanoic acid, and a glufosinate ammonium dehydrogenase mutant for catalytically reducing 2-carbonyl-4-[hydroxy(methyl)phosphonyl]butanoic acid to L-glufosinate ammonium. The glufosinate ammonium dehydrogenase mutant is obtained by mutation of glufosinate-ammonium dehydrogenase in wild fungi Thiopseudomonas denitrificans at a mutation site of V377S. The glufosinate ammonium dehydrogenase mutant in the present invention has better catalytic efficiency. When racemic D, L-glufosinate ammonium is used as a substrate for a catalytic reaction, the conversion rate is much higher than the conversion rate of a wild-type enzyme, and the yield of 2-carbonyl-4-[hydroxy(methyl)phosphonyl]butanoic acid (PPO for short) is also greatly improved.

A method of removing calculus from a tooth is described comprising: applying aqueous compositions A and B to the tooth surface, wherein the composition A comprises hydrogen peroxide or a precursor thereto and composition B comprises catalase and a stabilizer comprising hydroxyl groups; and removing at least a part of the calculus from the tooth surface. Preferred stabilizers include dipropylene glycol and 1,3 propane diol. Also described are aqueous compositions and kits.